Mersana Therapeutics Aktie (A2DTR7

Was macht Mersana Therapeutics?

Unternehmensprofil

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Chart der Mersana Therapeutics Aktie

Charttool öffnen

Aktuelle Nachrichten zu Mersana Therapeutics

Weitere Nachrichten

Unsere neuesten Artikel zu Mersana Therapeutics

Zusammenarbeit der Pharmakonzerne Merck und Mersana – Merck sichert sich Exklusivlizenz

Kooperation der Pharmakonzerne bei der Entwicklung zu immunstimulatorischer Antikörperwirkstoff Konjugate.

Das berichten andere über Mersana Therapeutics

Day One Bio (DAWN) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATETuesday, Feb. 24, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dr. Jeremy BenderChief Commercial Officer — Lauren MerendinoChief...

Day One Completes Acquisition of Mersana Therapeutics

Day One Bio today announced the successful close of its acquisition of Mersana Therapeutics, Inc.

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of...

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing...